France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.
That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a ...
On this episode of Louisiana Considered, we look at what’s on New Orleans‘ ballot ahead of the November elections and learn ...
The novel GLP-1 receptor agonists will likely reduce the need for CABG and improve surgical outcomes, several argue.
Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...
Three cities in Hawaii, Minnesota, and Texas report the highest usage of injectable weight loss medications. Meanwhile, ...
The pharmaceutical industry has seen a tremendous surge in the development of weight loss drugs, particularly GLP-1 receptor ...
Dear reader, in 2024, the pharmaceutical industry has undergone significant transformations due to rapid advancements in drug ...
Discover ADM's new solutions platform for GLP-1 consumers. With over 25 market-ready concepts, it assists those on ...
A growing number of employers are considering covering the blockbuster weight-loss drugs, several surveys show. Workers will ...
The report shows a rise in medication use, obesity, and smoking, a decline in cancer screenings, concerns over excessive ...